Ajanta Pharma Limited

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:51 2024-05-31 EDT			5-day change	1st Jan Change
2,333 ^INR	-3.27%		-3.69%	+11.97%

05-03	INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh	RE
05-02	Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4	MT

Madhu Verma Ceases to be Director of Ajanta Pharma Ltd

January 14, 2014 at 08:04 am

Ajanta Pharma Ltd. has announced that EXIM Bank has vide letter dated January 10, 2014 withdrawn nomination of Ms. Madhu Verma as Director of the company. Accordingly, Ms. Madhu Verma ceases to be Director of the company with immediate effect.

Latest news about Ajanta Pharma Limited

INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh	05-03	RE
Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4	05-02	MT
Ajanta Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-02	CI
Ajanta Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-02	CI
Ajanta Pharma Limited announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.	05-02	CI
Ajanta Pharma Limited Provides Revenue Guidance for the Fiscal Year 2025	05-02	CI
Transcript : Ajanta Pharma Limited, Q4 2024 Earnings Call, May 02, 2024	05-02
Ajanta Pharma Limited authorizes a Buyback Plan.	05-01	CI
Ajanta Pharma Limited?s Board intends to launch an Equity Buyback on May 2, 2024.	04-25	CI
Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit	02-02	MT
Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024	01-31
Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024	01-31	CI
Ajanta Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-31	CI
Ajanta Pharma Board to Consider Second Interim Dividend for Fiscal 2024	01-25	MT
Ajanta Pharma Limited Provides Earnings Guidance for the Full Year of Fiscal 2024	23-10-31	CI
Transcript : Ajanta Pharma Limited, Q2 2024 Earnings Call, Oct 31, 2023	23-10-31
Ajanta Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-31	CI
Ajanta Pharma Gets US FDA Nod for Topiramate Extended-Release Capsules	23-08-30	MT
Ajanta Pharma Limited Receives Final Approval from US FDA for Topiram Extended Release Capsules	23-08-30	CI
Ajanta Pharma Logs Increase in Fiscal Q1 Consolidated Profit	23-07-28	MT
Transcript : Ajanta Pharma Limited, Q1 2024 Earnings Call, Jul 27, 2023	23-07-27
Ajanta Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-27	CI
Ajanta Pharma Board to Consider Interim Dividend for Fiscal 2024	23-07-24	MT
Ajanta Pharma Limited Confirms the Interim Dividend for the Year Ended 31 March 2023	23-07-18	CI
Ajanta Pharma Gets No Observations After US FDA's Inspection of API Facility in Hyderabad, India	23-06-25	MT

Chart Ajanta Pharma Limited

Duration

Period

More charts

Company Profile

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ajanta Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,333 INR

Average target price

2,440 INR

Spread / Average Target

+4.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
AJANTA PHARMA LIMITED	+11.97%	3.49B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals

Ajanta Pharma Limited

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Madhu Verma Ceases to be Director of Ajanta Pharma Ltd

EPS Revisions